Bet Bromodomain Inhibitor Zen-3694
Recurrent Endometrial Clear Cell Adenocarcinoma
National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Recurrent Endometrial Clear Cell Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Floor Backes, MD | Phase 3 | BB |
Dasatinib National Cancer Institute (NCI) | Phase 2 | B |
Bms-907351 National Cancer Institute (NCI) | Phase 2 | B |
Lorigerlimab MacroGenics | Phase 2 | CCC |
Nivolumab Instituto do Cancer do Estado de São Paulo | Phase 2 | CCC |
View all 16 →
Same molecule, other indications
Bet Bromodomain Inhibitor Zen-3694 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →